RecruitingNCT06857084

Evaluation Of Outcomes Following Rotator Cuff Repair Using the REGENETEN Bioinductive Implant: A Prospective, Multi-Center Global Registry

Evaluation Of Clinical and Health Economic Outcomes Following Rotator Cuff Repair Using the REGENETEN◊ Bioinductive Implant: A Prospective, Multi-Center Global Registry


Sponsor

Smith & Nephew, Inc.

Enrollment

400 participants

Start Date

Oct 1, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients who are undergoing rotator cuff repair using the REGENETEN◊ Bioinductive Implant System. The Registry will include up to 50 centers in the United Kingdom (UK), Europe, Australia, and up to 400 patients for the initial evaluation. Patients will be treated and evaluated according to standard medical care. Outcome data is collected up to 2 years post-surgery.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Subject requires Arthroscopic rotator cuff repair (ARCR);
  • Patients aged over 18 years old at the time of consent and providing baseline data before undergoing rotator cuff repair surgery (either partial or full thickness tears) will be eligible for this prospective registry.

Exclusion Criteria3

  • Subject who, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the registry including mental illness, intellectual disability, and drug or alcohol abuse.
  • Subjects who do not meet the indication or are contraindicated according to specific Smith+Nephew REGENETEN System's Instructions for Use (IFUs);
  • Subject that meets the definition of a Vulnerable Subject per ISO14155:2020 Section 3.44.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEArthroscopic rotator cuff repair with REGENETEN Bioinductive Implant augmentation

Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue.


Locations(19)

Melbourne Orthopaedic Group

Windsor, Victoria, Australia

Clinique Saint Christophe

Soissons, Aisne, France

Schoen Klinik Lorsch

Lorsch, Rhine, Germany

Schoen Klinik Dusseldorf

Düsseldorf, Germany

Malteser Waldkrankenhaus Erlangen

Erlangen, Germany

Sporthopaedie Heidelberg

Heidelberg, Germany

St. Anna Hospital

Herne, Germany

OrthoMedicum Mittelhessen

Stadtallendorf, Germany

Regional General Hospital F. Miulli

Acquaviva delle Fonti, Apulia, Italy

Manchester University NHS Foundation Trust

Manchester, Greater Manchester, United Kingdom

Spire Harpenden Hospital

Harpenden, Hertordshire, United Kingdom

Spire Montefiore

Brighton, Hove, United Kingdom

Burnley General Hospital

Burnley, Lancashire, United Kingdom

Burnley General Teaching Hospital

Burnley, Lancashire, United Kingdom

Manchester University NHS Foundation Trust

Manchester, Lancashire, United Kingdom

Grantham and District Hospital

Grantham, Lincolnshire, United Kingdom

University College London Hospitals

London, London, United Kingdom

Cleveland Clinic London Hospital

London, London, United Kingdom

Sulis Hospital Bath

Bath, Somerset, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06857084


Related Trials